To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of a rolling NDA to FDA this quarter for setmelanotide to treat pro-opiomelanocortin and leptin receptor deficiency obesities.

Mirati Therapeutics Inc. (NASDAQ:MRTX) hired Daniel Faga as EVP and COO and Benjamin Hickey as

Read the full 669 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE